- Home
- SLN vs WSBF Comparison
SLN vs WSBF Comparison
Compare SLN & WSBF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- WSBF
- Stock Information
- Founded
- SLN 1994
- WSBF 1921
- Country
- SLN United Kingdom
- WSBF United States
- Employees
- SLN N/A
- WSBF N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- WSBF Savings Institutions
- Sector
- SLN Health Care
- WSBF Finance
- Exchange
- SLN Nasdaq
- WSBF Nasdaq
- Market Cap
- SLN 281.0M
- WSBF 261.3M
- IPO Year
- SLN N/A
- WSBF N/A
- Fundamental
- Price
- SLN $5.92
- WSBF $14.02
- Analyst Decision
- SLN Buy
- WSBF
- Analyst Count
- SLN 5
- WSBF 0
- Target Price
- SLN $32.60
- WSBF N/A
- AVG Volume (30 Days)
- SLN 111.7K
- WSBF 52.4K
- Earning Date
- SLN 08-14-2025
- WSBF 07-24-2025
- Dividend Yield
- SLN N/A
- WSBF 4.27%
- EPS Growth
- SLN N/A
- WSBF 95.86
- EPS
- SLN N/A
- WSBF 1.02
- Revenue
- SLN $27,701,000.00
- WSBF $133,551,000.00
- Revenue This Year
- SLN N/A
- WSBF N/A
- Revenue Next Year
- SLN N/A
- WSBF N/A
- P/E Ratio
- SLN N/A
- WSBF $13.57
- Revenue Growth
- SLN N/A
- WSBF 1.81
- 52 Week Low
- SLN $1.97
- WSBF $11.61
- 52 Week High
- SLN $22.47
- WSBF $16.86
- Technical
- Relative Strength Index (RSI)
- SLN 58.35
- WSBF 63.78
- Support Level
- SLN $5.33
- WSBF $13.60
- Resistance Level
- SLN $6.00
- WSBF $14.12
- Average True Range (ATR)
- SLN 0.44
- WSBF 0.23
- MACD
- SLN -0.03
- WSBF 0.01
- Stochastic Oscillator
- SLN 64.07
- WSBF 70.33
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About WSBF Waterstone Financial Inc. (MD)
Waterstone Financial Inc is a holding company. Through its subsidiaries, it operates in two reportable segments: Community Banking and Mortgage Banking. The Community Banking segment provides consumer and business banking products and services to customers, which include various types of loans, deposits, and personal investment services. The Mortgage Banking segment involves residential mortgage loans for the primary purpose of sale in the secondary market. The vast majority of its revenue comes from the Community Banking segment.